Monitoring Heparin Therapy with APTT

Introduction to APTT Monitoring

The American College of Cardiology and the American Heart Association recommend monitoring heparin therapy using the activated partial thromboplastin time (APTT) to measure the time required for clot formation in the intrinsic and common coagulation pathways, which are prolonged when heparin binds to antithrombin (AT) and accelerates the inactivation of factors IIa, Xa, IXa, XIa, and XIIa 1, 2

Heparin requires antithrombin as a cofactor to exert its anticoagulant effect, with only heparin molecules containing a specific high-affinity pentasaccharide sequence binding to AT, causing a conformational change that accelerates AT's ability to inactivate coagulation factors by approximately 1000-fold 1, 3
The heparin-AT complex primarily inhibits thrombin and factor Xa, with additional effects on factors IXa, XIa, and XIIa, which are components measured by the APTT test 1, 2

The APTT prolongation correlates with plasma heparin concentration because higher heparin levels produce greater inhibition of the coagulation factors measured in the assay, with a therapeutic APTT range of 1.5 to 2.5 times control corresponding to heparin levels of 0.3-0.7 units/mL by anti-Xa assay 2, 5
Subtherapeutic APTT values are associated with a 15-fold increased risk of recurrent venous thromboembolism, demonstrating that inadequate APTT prolongation reflects insufficient anticoagulation 1, 6, 7

Different APTT reagents and coagulometers produce vastly different results for the same heparin concentration, with the same heparin level producing APTT values ranging from 48 to 108 seconds depending on the reagent used 2, 5, 8
Each institution must establish its own therapeutic APTT range calibrated to the specific reagent and coagulometer used, as no universal nomogram applies to all APTT reagents 1, 2, 5
Heparin binds nonspecifically to plasma proteins, endothelial cells, and macrophages, causing variable anticoagulant responses and the phenomenon of "heparin resistance" 1, 3

Measure APTT 6 hours after the initial heparin bolus dose, as this allows time for steady-state distribution and reflects the anticoagulant effect of the continuous infusion 1, 6
Adjust heparin doses according to weight-based nomograms targeting an APTT of 60-85 seconds, with the American College of Chest Physicians recommending a target APTT range of 1.5-2.5 times control 1, 2, 6, 7

Do not assume a "therapeutic" APTT of 1.5-2.5 times control is appropriate for your institution's reagent, as this range must be validated against anti-Xa levels for your specific laboratory conditions 2, 5
Do not ignore persistently subtherapeutic APTT values, as even APTT of 50-59 seconds carries significantly increased thrombotic risk, according to the American Heart Association 1, 6, 7